The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Open accessAbstract
Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. Cancer Discov; 4(9); 998–1013. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2576 · Cited by 1,047
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · cited 1×
“This new murine stroma probably results in changes in paracrine regulation of the tumor as well as in physical properties such as interstitial pressure, that may limit the study of agents directed against this tumor compartment (50, 60).”
BackgroundDeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 8×
“Furthermore, the analysis of clinically validated biomarkers, such as KRAS mutations, and resistance to EGFR inhibitors in PDX studies reached the same conclusions as clinical trials, as discussed in more detail below (28).”
BackgroundMethodResultInfluentialSelf-citationSaal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Reconstruction of functionally normal and malignant human breast tissues in mice
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A., & Weinberg, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401064101 · Cited by 804
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Single-cell dissection of transcriptional heterogeneity in human colon tumors
Dalerba, P., Kalisky, T., Sahoo, D., Rajendran, P. S., Rothenberg, M. E., Leyrat, A. A., Sim, S., Okamoto, J., Johnston, D. M., Qian, D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.2038 · Cited by 703
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 669
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Self-citationLi, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Anido, J., Sáez-Borderías, A., Gonzàlez-Juncà, A., Rodón, L., Folch, G., Carmona, M. A., Prieto-Sánchez, R. M., Barba, I., Martínez-Sáez, E., Prudkin, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.023 · Cited by 572
Self-citationSerra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., Landis, M. D., Wiechmann, L., Schiff, R., Giuliano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4081 · Cited by 481
Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477 · cited 3×
“Key methodologic aspects of selected PDX collections Reference Tumor type Available models Origin Procurement Processing Mice strain Implantation site Engraftment rate (28) CRC 130 Metastasis Surgery Fresh tumor pieces in Matrigel NOD/SCID s.c. 87% (29) CRC 54 Primary (35) Metastasis (19) Surgery Fresh tumor pieces Nu…”
BackgroundInfluentialChan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“In their original format, these studies refer to the use of GEMMs of cancer to determine patient selection strategies as well as to discover mechanisms of resistance to treatment approaches (51, 52).”
BackgroundHow basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Yuan, Y., Failmezger, H., Rueda, O. M., Ali, H. R., Gräf, S., Chin, S.-F., Schwarz, R. F., Curtis, C., Dunning, M. J., Bardwell, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004330 · Cited by 426
Self-citationA New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 422
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
Self-citationHidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Self-citationLonardo, E., Hermann, P. C., Mueller, M.-T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J. C., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.10.001 · Cited by 405
Self-citationAromatase, aromatase inhibitors, and breast cancer
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Self-citationGeneration of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
Kim, M. P., Evans, D. B., Wang, H., Abbruzzese, J. L., Fleming, J. B., & Gallick, G. E. (2009) · Nature Protocols · doi:10.1038/nprot.2009.171 · Cited by 380
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360
Self-citationSaal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
Mueller, M., Hermann, P. C., Witthauer, J., Rubio–Viqueira, B., Leicht, S. F., Huber, S., Ellwart, J. W., Mustafa, M., Bartenstein, P., D'Haese, J. G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.053 · Cited by 348
Self-citationChakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
The Genetic Basis for Cancer Treatment Decisions
Dancey, J. E., Bedard, P. L., Onetto, N., & Hudson, T. J. (2012) · Cell · doi:10.1016/j.cell.2012.01.014 · Cited by 343
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 340
Kondo, J., Endo, H., Okuyama, H., Ishikawa, O., Iishi, H., Tsujii, M., Ohue, M., & Inoue, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015938108 · Cited by 322 · cited 1×
“These tissue-originated spheroids are generated by digesting and growing primary tumor cells under controlled culture conditions (62).”
BackgroundAntiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 317
López‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24831 · Cited by 302
Song, R. X.-D., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., & Santen, R. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1714 · Cited by 293
Clonogenic assay with established human tumour xenografts
Fiebig, H. H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 291
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288 · cited 2×
“In addition to bioinformatics and in silico prediction data from cancer cell line data, personalized PDX models may now be useful in this setting, as they facilitate testing of candidate regimens in the patient’s own tumor to select for the most efficacious treatment approach (3, 59).”
BackgroundEllis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., Dickler, M. N., Silverman, P., Fleming, G. F., Kommareddy, A., et al. (2009) · JAMA · doi:10.1001/jama.2009.1204 · Cited by 287
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286
Slinker, B. K. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0655 · Cited by 277
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Garrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
Self-citationAnticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
Selwood, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602070 · Cited by 238
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Chong, K., Peng, L., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234
Lønning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jørgensen, L.-M., Mella, O., & Howell, A. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010619225209 · Cited by 226
Akt inhibitors in clinical development for the treatment of cancer
Pal, S. K., Reckamp, K., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 226
DeRose, Y. S., Gligorich, K. M., Wang, G., Georgelas, A., Bowman, P., Courdy, S. J., Welm, A. L., & Welm, B. E. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1423s60 · Cited by 226
Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Lin, L., Hoog, J., Goiffon, R. J., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 225
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
Stossi, F., Barnett, D. H., Frasor, J., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Endocrinology · doi:10.1210/en.2003-1682 · Cited by 219
Marty, B., Maire, V., Gravier, E., Rigaill, G., Vincent-Salomon, A., Kappler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216
The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells
Lebedeva, I. V., Su, Z.-Z., Chang, Y., Kitada, S., Reed, J. C., & Fisher, P. B. (2002) · Oncogene · doi:10.1038/sj.onc.1205116 · Cited by 205
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003643 · Cited by 193
Molecular profiling of patient-derived breast cancer xenografts
Reyal, F., Guyader, C., Decraene, C., Lucchesi, C., Auger, N., Assayag, F., De Plater, L., Gentien, D., Poupon, M.-F., Cottu, P., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3095 · Cited by 192
Self-citationMigliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191 · cited 1×
“The MEK and PI3K/mTOR inhibitors proved to be poorly effective in a panel of 40 KRAS-mutant colorectal cancer PDX models, again in accordance with clinical data from phase I trials (37).”
BackgroundSelf-citationWelm, B. E., Dijkgraaf, G. J. P., Bledau, A. S., Welm, A. L., & Werb, Z. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.10.002 · Cited by 190
Fitzgibbons, P. L., Dillon, D. A., Alsabeh, R., Berman, M. A., Hayes, D. F., Hicks, D. G., Hughes, K. S., & Nofech-Mozes, S. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0566-cp · Cited by 188
Dong, X., Guan, J., English, J. C., Flint, J., Yee, J., Evans, K., Murray, N., MacAulay, C., Ng, R. T., Gout, P. W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2878 · Cited by 188
Bioluminescent imaging: a critical tool in pre‐clinical oncology research
O'Neill, K., Lyons, S. K., Gallagher, W. M., Curran, K. M., & Byrne, A. T. (2010) · The Journal of Pathology · doi:10.1002/path.2656 · Cited by 174
Self-citationKeysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., Paylor, J. J., Glogowska, M. J., Le, P. N., Eagles-Soukup, J. R., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.03.004 · Cited by 167
Némati, F., Sastre-Garau, X., Laurent, C., Couturier, J., Mariani, P., Desjardins, L., Piperno-Neumann, S., Lantz, O., Asselain, B., Plancher, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3066 · Cited by 165
Self-citationSebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
Self-citationEmbuscado, E. E., Laheru, D. A., Ricci, F., Yun, K. J., Witzel, S. D. B., Seigel, A., Flickinger, K., Hidalgo, M. M., Bova, G. S., & Iacobuzio–Donahue, C. A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.5.1663 · Cited by 151
Self-citationPhenotypic instability of Saos-2 cells in long-term culture
Hausser, H., & Brenner, R. E. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.097 · Cited by 145
The APL Paradigm and the “Co-Clinical Trial” Project
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L. C., & Pandolfi, P. P. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0061 · Cited by 130
A Model for Personalized in Vivo Analysis of Human Immune Responsiveness
Kalscheuer, H., Danzl, N. M., Onoe, T., Faust, T., WINCHESTER, R. J., Goland, R., Greenberg, E. M., Spitzer, T. R., Savage, D. G., Tahara, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003481 · Cited by 130
Moestue, S. A., Borgan, E., Huuse, E. M., Lindholm, E. M., Sitter, B., Børresen‐Dale, A., Engebraaten, O., Mælandsmo, G. M., & Gribbestad, I. S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-433 · Cited by 122
Self-citationDeforolimus (AP23573) a novel mTOR inhibitor in clinical development
Mita, M. M., Sankhala, K. K., Abdel-Karim, I., Mita, A. C., & Giles, F. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802556485 · Cited by 119
Rivera, V. M., Squillace, R. M., Miller, D., Berk, L., Wardwell, S., Ning, Y., Pollock, R. M., Narasimhan, N. I., Iuliucci, J. D., Wang, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0792 · Cited by 114
Sabnis, G. J., Jelovac, D., Long, B. J., & Brodie, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4092 · Cited by 111
Masri, S., Phung, S., Wang, X., Wu, X., Yuan, Y., Wagman, L. D., & Chen, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0303 · Cited by 110
Kimple, R. J., Harari, P. M., Torres, A. D., Yang, R., Soriano, B. J., Yu, M., Armstrong, E. A., Blitzer, G. C., Smith, M. A., Lorenz, L. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2746 · Cited by 110
Vidal, A., Muñoz, C., Guillén, M.-J., Moretó, J., Puertas, S., Martínez‐Iniesta, M., Figueras, A., Padullés, L., García-Rodríguez, F. J., Berdiel‐Acer, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1513 · Cited by 108
Self-citationHR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Moestue, S. A., Sitter, B., Bathen, T. F., Tessem, M., & Gribbestad, I. S. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611793611869 · Cited by 107
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts
Cottu, P. H., Marangoni, E., Assayag, F., de Crémoux, P., Vincent‐Salomon, A., Guyader, C., de Plater, L., Ganem‐Elbaz, C., Karboul, N., Fontaine, J. J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1815-5 · Cited by 105
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
Rajeshkumar, N. V., Tan, A. C., Oliveira, E. D., Womack, C., Wombwell, H., Morgan, S. R., Warren, M. V., Walker, J., Green, T. P., Jimeno, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3021 · Cited by 97
Self-citationHartford, C. M., Desai, A. A., Janisch, L. A., Karrison, T. G., Rivera, V. M., Berk, L., Loewy, J. W., Kindler, H. L., Stadler, W. M., Knowles, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2076 · Cited by 96
Venditti, J. M., WESLEY, R. A., & Plowman, J. (1984) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60263-x · Cited by 94
Floc’h, N., Kinkade, C. W., Kobayashi, T., Aytés, À., Lefèbvre, C., Mitrofanova, A., Cardiff, R. D., Califano, A., Shen, M. M., & Abate-Shen, C. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0283 · Cited by 91
Reyes, G., Villanueva, A., García, C., Sancho, F. J., Piulats, J. M., Lluı́s, F., & Capellá, G. (1996) · PubMed · Cited by 90
Self-citationBidard, F., Conforti, R., Boulet, T., Michiels, S., Delaloge, S., & André, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm360 · Cited by 87
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Garrido‐Laguna, I., Tan, A. C., Uson, M. L., Angenendt, M., W, W., Villaroel, M. C., Zhao, M., Rajeshkumar, N. V., Jimeno, A., Donehower, R. C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605819 · Cited by 84
Self-citationMurphy, C. S., Pink, J. J., & Jordan, V. C. (1990) · PubMed · Cited by 84
Weiswald, L., Richon, S., Validire, P., Briffod, M., Lai–Kuen, R., Cordelières, F. P., Bertrand, F., Dargère, D., Massonnet, G., Marangoni, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605173 · Cited by 81
Yen, W.-C., Fischer, M. M., Hynes, M. J., Wu, J., Kim, E. J.-H., Beviglia, L., Yeung, V. P., Song, X., Kapoun, A. M., Lewicki, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0736 · Cited by 71
Development of Three Human Small Cell Lung Cancer Models in Nude Mice
Fiebig, H., Neumann, H., Henß, H., Koch, H.-G., Kaiser, D., & Arnold, H. (1985) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-82372-5_8 · Cited by 63
Increased phosphorylation of Akt in triple‐negative breast cancers
Umemura, S., Yoshida, S., Ohta, Y., Naito, K., OSAMURA, R. Y., & Tokuda, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00622.x · Cited by 62
Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State
Obiorah, I. E., Fan, P., & Jordan, V. C. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0061 · Cited by 62
Dourdin, N., Schade, B., Lesurf, R., Hallett, M. T., Munn, R. J., Cardiff, R. D., & Muller, W. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5727 · Cited by 62
Aytés, À., Molleví, D. G., Martínez‐Iniesta, M., Nadal, M., Vidal, A., Morales, A., Salazar, R., Capellá, G., & Villanueva, A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20843 · Cited by 61
Self-citationSessa, C., Tosi, D., Viganò, L., Albanell, J., Hess, D., Maur, M., Cresta, S., Locatelli, A., Angst, R., Rojo, F., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp504 · Cited by 59
Iwase, H., Yamamoto, Y., Yamamoto‐Ibusuki, M., Murakami, K.-I., Okumura, Y., Tomita, S., Inao, T., Honda, Y., Omoto, Y., & Iyama, K.-I. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.520 · Cited by 57
Rapamycin induces transactivation of the EGFR and increases cell survival
Chaturvedi, D., Gao, X., Cohen, M. S., Taunton, J., & Patel, T. B. (2009) · Oncogene · doi:10.1038/onc.2008.490 · Cited by 55
van der Meel, R., Gallagher, W. M., Oliveira, S., O’Connor, A. E., Schiffelers, R. M., & Byrne, A. T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.12.003 · Cited by 52
Self-citationPreclinical xenograft models of human sarcoma show nonrandom loss of aberrations
Kresse, S. H., Meza‐Zepeda, L. A., Machado, I., Llombart‐Bosch, A., & Myklebost, O. (2011) · Cancer · doi:10.1002/cncr.26276 · Cited by 50
Targeting the mTOR Pathway Using Deforolimus in Cancer Therapy
Mahalingam, D., Sankhala, K. K., Mita, A. C., Giles, F. J., & Mita, M. M. (2009) · Future Oncology · doi:10.2217/fon.09.9 · Cited by 48
Saito, Y., Miyahara, R., Gopalan, B., Litvak, A. M., Inoue, S., Shanker, M., Branch, C. D., Mhashilkar, A. M., Roth, J. A., Chada, S., et al. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700780 · Cited by 43
Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers
Rexer, B. N., Ghosh, R., & Arteaga, C. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0872 · Cited by 41
Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton, J. A., Houghton, P. J., & Green, A. A. (1982) · PubMed · Cited by 40
Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor
Li, Y. (2009) · Cancer Research · Cited by 40
Moestue, S. A., Huuse, E. M., Lindholm, E. M., Bofin, A. M., Engebraaten, O., Mælandsmo, G. M., Akslen, L. A., & Gribbestad, I. S. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24079 · Cited by 34
Self-citationPersonalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Kamiyama, H., Rauenzahn, S. L., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., Kamiyama, M., Schuler, F. W., Lin, M., Beaty, R. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2127 · Cited by 33
Self-citationAssessment of celecoxib pharmacodynamics in pancreatic cancer
Jimeno, A., Amador, M. L., Kulesza, P., Wang, X., Rubio‐Viqueira, B., Zhang, X., Chan, A., Wheelhouse, J., Kuramochi, H., Tanaka, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0565 · Cited by 33
Self-citationCalles, A., Rubio‐Viqueira, B., & Hidalgo, M. M. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1426s61 · Cited by 32
Self-citationGetting personalized cancer genome analysis into the clinic: the challenges in bioinformatics
Valencia, A., & Hidalgo, M. M. (2012) · Genome Medicine · doi:10.1186/gm362 · Cited by 31
Self-citationHuman Tumor Xenografts and Explants
Fiebig, H., & Burger, A. M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-100-8_7 · Cited by 28
Estrogen signaling pathway and its imaging in human breast cancer
Hayashi, S., Niwa, T., & Yamaguchi, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01243.x · Cited by 28
Metcalf, C. A., Bohacek, R. S., Rozamus, L. W., Burns, K. D., Roses, J. B., Rivera, V. M., Tang, H., Keats, J. A., Dalgarno, D. C., Snodgrass, J. T., et al. (2004) · Cancer Research · Cited by 22
Agrawal, A., Robertson, J. F. R., & Cheung, K. (2006) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-4-44 · Cited by 20
Zucchini, G., Armstrong, A. C., Wardley, A. M., Wilson, G., Misra, V., Seif, M. W., Ryder, W. D. J., Cope, J., Blowers, E., Howell, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.028 · Cited by 18
Kleine, W. (1986) · Gynecologic Oncology · doi:10.1016/0090-8258(86)90066-1 · Cited by 15
Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells
Zheng, J., Hudder, A., Zukowski, K. L., & NOVAK, R. F. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.018 · Cited by 11
Cited by
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Metadata
- Authors
- Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., Roman-Roman, S., Seoane, J., Trusolino, L., Villanueva, A., & for the EurOPDX Consortium
- Venue
- Cancer Discovery
- Published
- 2014-09-01
- Volume
- 4
- Issue
- 9
- Pages
- 998-1013
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2118952409
- Cited by
- 1,742
- References
- 140
- FWCI
- 46.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.